Loading...
•
Dec 31, 2019
Collegium Q4 2019 Earnings Report
Collegium reported full-year revenue and revenue growth driven by Xtampza ER.
Key Takeaways
Collegium announced record revenue for 2019, driven by Xtampza ER growth and the acquisition of the Nucynta Franchise. The company is guiding to profitability in 2020.
Delivered record revenue in 2019.
Achieved non-GAAP profitability for three consecutive quarters.
Xtampza ER revenue growth of 51% in 2019.
Xtampza ER Prescriptions Grew 49% in 2019.
Forward Guidance
Collegium reiterates its full-year 2020 financial guidance and anticipates a financially transformative year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...